GRL 0617

Key Product Details

Product Description

GRL 0617 is a coronavirus papain-like protease (Plpro) inhibitor (IC₅₀ values are 0.6 and 0.8 μM for SARS-COV and SARS-CoV-2 PLpro, respectively). Inhibits deubiquitination activity of SARS-CoV PLpro. Displays no inhibition of human deubiquitinating enzymes. Improves cell viability following SARS-CoV infection. Inhibits SARS-CoV-2 viral replication and induces antiviral immune signaling pathways following SARS-CoV-2 infection in CaCo-2 cells.

Product Specifications for GRL 0617

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for GRL 0617

The following data is based on the product molecular weight 304.39.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.29 mL	16.43 mL	32.85 mL
5 mM	0.66 mL	3.29 mL	6.57 mL
10 mM	0.33 mL	1.64 mL	3.29 mL
50 mM	0.07 mL	0.33 mL	0.66 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Freitas Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-Like protease. ACS Infect.Dis. 2020 PMID: 32428392
• Shin Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 2020 PMID: 32726803
• Ratia A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc.Natl.Acad.Sci.USA. 2008 PMID: 18852458

Product Documents for GRL 0617